These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 23442768)
1. Regional differences in prostaglandin E₂ metabolism in human colorectal cancer liver metastases. Young AL; Chalmers CR; Hawcroft G; Perry SL; Treanor D; Toogood GJ; Jones PF; Hull MA BMC Cancer; 2013 Feb; 13():92. PubMed ID: 23442768 [TBL] [Abstract][Full Text] [Related]
2. miR-21-mediated regulation of 15-hydroxyprostaglandin dehydrogenase in colon cancer. Monteleone NJ; Moore AE; Iacona JR; Lutz CS; Dixon DA Sci Rep; 2019 Apr; 9(1):5405. PubMed ID: 30931980 [TBL] [Abstract][Full Text] [Related]
3. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. Backlund MG; Mann JR; Holla VR; Buchanan FG; Tai HH; Musiek ES; Milne GL; Katkuri S; DuBois RN J Biol Chem; 2005 Feb; 280(5):3217-23. PubMed ID: 15542609 [TBL] [Abstract][Full Text] [Related]
4. 15-Prostaglandin Dehydrogenase Inhibition Enhances Colon Cancer Metastasis by Up-regulation of Epithelial-to-Mesenchymal Transition Genes. Kim SH; Song SE; Baik H; Hur DY; Kang MS; Bae KB Anticancer Res; 2022 Nov; 42(11):5385-5396. PubMed ID: 36288851 [TBL] [Abstract][Full Text] [Related]
5. Genetic variability in key genes in prostaglandin E2 pathway (COX-2, HPGD, ABCC4 and SLCO2A1) and their involvement in colorectal cancer development. Pereira C; Queirós S; Galaghar A; Sousa H; Pimentel-Nunes P; Brandão C; Moreira-Dias L; Medeiros R; Dinis-Ribeiro M PLoS One; 2014; 9(4):e92000. PubMed ID: 24694755 [TBL] [Abstract][Full Text] [Related]
6. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) prevents lipopolysaccharide (LPS)-induced acute liver injury. Yao L; Chen W; Song K; Han C; Gandhi CR; Lim K; Wu T PLoS One; 2017; 12(4):e0176106. PubMed ID: 28423012 [TBL] [Abstract][Full Text] [Related]
7. Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer. Kochel TJ; Fulton AM Prostaglandins Other Lipid Mediat; 2015; 116-117():99-103. PubMed ID: 25433169 [TBL] [Abstract][Full Text] [Related]
8. 15-hydroxyprostaglandin dehydrogenase-derived 15-keto-prostaglandin E2 inhibits cholangiocarcinoma cell growth through interaction with peroxisome proliferator-activated receptor-γ, SMAD2/3, and TAP63 proteins. Lu D; Han C; Wu T J Biol Chem; 2013 Jul; 288(27):19484-502. PubMed ID: 23687300 [TBL] [Abstract][Full Text] [Related]
9. Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma. Castro-Sánchez L; Agra N; Llorente Izquierdo C; Motiño O; Casado M; Boscá L; Martín-Sanz P Int J Biochem Cell Biol; 2013 Nov; 45(11):2501-11. PubMed ID: 23954207 [TBL] [Abstract][Full Text] [Related]
10. A potential anti-tumor effect of leukotriene C4 through the induction of 15-hydroxyprostaglandin dehydrogenase expression in colon cancer cells. Mehdawi LM; Satapathy SR; Gustafsson A; Lundholm K; Alvarado-Kristensson M; Sjölander A Oncotarget; 2017 May; 8(21):35033-35047. PubMed ID: 28402256 [TBL] [Abstract][Full Text] [Related]
11. Understanding human 15-hydroxyprostaglandin dehydrogenase binding with NAD+ and PGE2 by homology modeling, docking and molecular dynamics simulation. Hamza A; Cho H; Tai HH; Zhan CG Bioorg Med Chem; 2005 Jul; 13(14):4544-51. PubMed ID: 15908215 [TBL] [Abstract][Full Text] [Related]
12. β-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells. Smartt HJ; Greenhough A; Ordóñez-Morán P; Talero E; Cherry CA; Wallam CA; Parry L; Al Kharusi M; Roberts HR; Mariadason JM; Clarke AR; Huelsken J; Williams AC; Paraskeva C Gut; 2012 Sep; 61(9):1306-14. PubMed ID: 22082586 [TBL] [Abstract][Full Text] [Related]
13. Prostaglandin E2 regulates its own inactivating enzyme, 15-PGDH, by EP2 receptor-mediated cervical cell-specific mechanisms. Kishore AH; Owens D; Word RA J Clin Endocrinol Metab; 2014 Mar; 99(3):1006-18. PubMed ID: 24471568 [TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice. Wang D; Fu L; Sun H; Guo L; DuBois RN Gastroenterology; 2015 Dec; 149(7):1884-1895.e4. PubMed ID: 26261008 [TBL] [Abstract][Full Text] [Related]
16. NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Hughes D; Otani T; Yang P; Newman RA; Yantiss RK; Altorki NK; Port JL; Yan M; Markowitz SD; Mazumdar M; Tai HH; Subbaramaiah K; Dannenberg AJ Cancer Prev Res (Phila); 2008 Sep; 1(4):241-9. PubMed ID: 19138967 [TBL] [Abstract][Full Text] [Related]
17. 15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE2/PPARγ-mediated activation of p21WAF1/Cip1. Lu D; Han C; Wu T Oncogene; 2014 Feb; 33(9):1101-12. PubMed ID: 23542179 [TBL] [Abstract][Full Text] [Related]
18. Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer. Kochel TJ; Reader JC; Ma X; Kundu N; Fulton AM Oncotarget; 2017 Jan; 8(4):6540-6554. PubMed ID: 28029661 [TBL] [Abstract][Full Text] [Related]
19. Antinidatory effect of luteal phase administration of mifepristone (RU486) is associated with changes in endometrial prostaglandins during the implantation window. Nayak NR; Sengupta J; Ghosh D Contraception; 1998 Aug; 58(2):111-7. PubMed ID: 9773266 [TBL] [Abstract][Full Text] [Related]
20. Prostaglandin E Kim HB; Kim M; Park YS; Park I; Kim T; Yang SY; Cho CJ; Hwang D; Jung JH; Markowitz SD; Hwang SW; Yang SK; Lim DS; Myung SJ Gastroenterology; 2017 Feb; 152(3):616-630. PubMed ID: 27864128 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]